IP Library Granted Patent US 9,902,974
Granted Patent B2
US 9,902,974 · App. 14/965,629 · Granted Feb 27, 2018

Methods and compositions for treatment of a genetic condition

Inventors: Anthony Conway (Richmond, CA); Gregory J. Cost (Richmond, CA); Russell DeKelver (Richmond, CA); Edward J. Rebar (Richmond, CA); Andreas Reik (Richmond, CA); Fyodor Urnov (Richmond, CA); Jianbin Wang (Richmond, CA); H. Steve Zhang (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/907C07K2/00C12N9/22C12N15/11C12N15/90C12N15/902C07K2319/81C12N2320/30C12Y301/21004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,974
App. No.
14/965,629
Granted
Feb 27, 2018
Kind
B2
Abstract

Methods and compositions comprising a fusion protein comprising a Cas protein and a functional domain in association with a single guide RNA targeted to an endogenous gene for genetic alteration of cells are provided.

Claims (7)

1. A fusion protein comprising a Cas protein and a functional domain in association with a single-guide RNA comprising a sequence selected from the group consisting of SEQ ID NOs:149-158 and 167-215.

2. The fusion protein of claim 1 , wherein the functional domain is a transcriptional activation domain, a transcriptional repression domain or a nuclease domain.

3. The fusion protein of claim 2 , wherein the nuclease domain is a FokI endonuclease domain.

4. The fusion protein of claim 3 , wherein the FokI endonuclease domain comprises one or more mutations in the dimerization domain.

5. A dimer comprising first and second fusion proteins according to claim 3 .

6. The dimer of claim 5 , wherein the first fusion protein comprises a FokI endonuclease domain comprising one or more mutations in the catalytic domain.

7. A pharmaceutical composition comprising a fusion protein according to claim 1 .

Assignments (1)
CHANGE OF NAME Recorded Oct 12, 2017
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 044229/0714 →
Continuity (3)
Continuation 14278903 · May 15, 2014
Provisional Application 61823689 · May 15, 2013
Related Publication 20160090607A1 · Mar 31, 2016